The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ping-Hung KoMeng Hsuan KuoI-Ting KaoChen-Yi WuChih-Wei TsengShih-Chieh ShaoPublished in: Viruses (2024)
cannot be ignored but may be avoided. Clinicians should consider implementing appropriate antiviral prophylaxis and monitoring policies for RA patients to avoid unnecessary hepatic side effects from tocilizumab treatment.
Keyphrases
- rheumatoid arthritis
- hepatitis b virus
- disease activity
- end stage renal disease
- ejection fraction
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- ankylosing spondylitis
- public health
- chronic kidney disease
- interstitial lung disease
- prognostic factors
- liver failure
- palliative care
- quality improvement
- systemic lupus erythematosus
- combination therapy
- idiopathic pulmonary fibrosis